Special Issue

Clinical Advances in the Neuropharmacological Treatment of Substance Use Disorders: 2nd Edition

Message from the Guest Editor

The clinical management of substance use disorders is becoming increasingly complex due to significant changes in drug use patterns over recent years. As a result, clinicians are increasingly required to stay informed about evolving drug trends, detection methods, and emerging therapeutic strategies. This Special Issue focuses on clinically relevant advances in the neuropharmacology and toxicology of substance use disorders. It aims to support healthcare professionals in improving the identification, risk assessment, and the treatment of individuals affected by both traditional and emerging substances of abuse. The journal Pharmaceuticals invites the submissions of reviews, meta-analyses, clinical case series, and original research articles. Topics of interest include, but are not limited to, the following areas:-

- Clinical neuropharmacology and toxicology of substances of abuse;
- Pharmacological and behavioural treatment strategies for substance use disorders:
- Emerging drug trends, including prescription misuse and NPS:
- Clinical screening, diagnostic tools, and early intervention approaches.

Guest Editor

Dr. Stefania Chiappini

Department of Human and Clinical Sciences, UniCamillus International University of Medical Sciences, Via di S. Alessandro 8, Rome, Italy

Deadline for manuscript submissions

25 January 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/244689

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

